Phagenesis, a medical device company specializing in the treatmentof swallowing disorders, successfully closes a $42M Series Dfinancing round led by EQT Life Sciences and Sectoral AssetManagement
Manchester, England (ots/PRNewswire)
-
Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment round. The combined...
Zur Pressemeldung auf www.ots.at